Astellas Pharma
Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). On February 5, 2020, the company announced management changes effective from April 1, 2020.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Adenocard | Adenosine | 1989-10-30 | — | |
| Adenoscan | Adenosine | 1995-05-18 | — | |
| Advagraf | Tacrolimus | 2007-04-23 | 2024-2028 | |
| Ambisome | Amphotericin b | 1997-08-11 | ||
| Amevive | Alefacept | 2003-01-30 | ||
| Aristocort | Triamcinolone | 1982-01-01 | 2027-2034 | |
| Aristocort a | Triamcinolone | 1982-01-01 | 2027-2034 |
1
2
3
4
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
17
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use